Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was downgraded by research analysts at Vetr from a “strong-buy” rating to a “buy” rating in a note issued to investors on Monday, July 31st. They currently have a $6.74 price objective on the biotechnology company’s stock. Vetr‘s target price points to a potential upside of 11.40% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the company. FBR & Co set a $11.00 price target on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, April 8th. HC Wainwright dropped their price target on Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, May 18th. Cantor Fitzgerald restated a “buy” rating and issued a $14.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, April 21st. BidaskClub cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Zacks Investment Research cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $9.28.
Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) traded up 5.95% on Monday, hitting $6.05. The stock had a trading volume of 1,287,699 shares. The stock has a 50 day moving average price of $6.34 and a 200-day moving average price of $6.16. Aurinia Pharmaceuticals has a 12-month low of $1.74 and a 12-month high of $10.54. The company’s market cap is $503.80 million.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. The business had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 38.20% and a negative net margin of 16,648.93%. On average, equities analysts expect that Aurinia Pharmaceuticals will post ($0.74) earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in the company. AWM Investment Company Inc. acquired a new position in Aurinia Pharmaceuticals during the first quarter valued at about $2,202,000. Morgan Stanley boosted its position in Aurinia Pharmaceuticals by 11,061.7% in the first quarter. Morgan Stanley now owns 446,135 shares of the biotechnology company’s stock valued at $3,273,000 after buying an additional 442,138 shares during the last quarter. UBS Group AG boosted its position in Aurinia Pharmaceuticals by 13.6% in the first quarter. UBS Group AG now owns 112,314 shares of the biotechnology company’s stock valued at $824,000 after buying an additional 13,405 shares during the last quarter. Monashee Investment Management LLC acquired a new position in Aurinia Pharmaceuticals during the first quarter valued at about $1,835,000. Finally, FMR LLC acquired a new position in Aurinia Pharmaceuticals during the first quarter valued at about $42,928,000. Institutional investors own 29.48% of the company’s stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.